Gain Therapeutics Inc (GANX)

$1.21

-0.01

(-0.82%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $1.21
    $1.23
    $1.21
    downward going graph

    0.0%

    Downside

    Day's Volatility :1.63%

    Upside

    1.63%

    downward going graph
  • $1.11
    $5.33
    $1.21
    downward going graph

    8.26%

    Downside

    52 Weeks Volatility :79.17%

    Upside

    77.3%

    downward going graph

Returns

PeriodGain Therapeutics IncIndex (Russel 2000)
3 Months
-61.83%
0.0%
6 Months
-64.62%
0.0%
1 Year
-72.5%
0.0%
3 Years
-86.85%
-19.4%

Highlights

Market Capitalization
30.7M
Book Value
$0.48
Earnings Per Share (EPS)
-1.5
Wall Street Target Price
7.6
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-74.54%
Return On Equity TTM
-177.83%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-7.7M
EBITDA
-21.4M
Diluted Eps TTM
-1.5
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.83
EPS Estimate Next Year
-0.96
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.32

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Gain Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 528.1%

Current $1.21
Target $7.60

Technicals Summary

Sell

Neutral

Buy

Gain Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gain Therapeutics Inc
Gain Therapeutics Inc
-6.92%
-64.62%
-72.5%
-86.85%
-89.2%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gain Therapeutics Inc
Gain Therapeutics Inc
NA
NA
NA
-0.83
-1.78
-0.75
NA
0.48
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gain Therapeutics Inc
Gain Therapeutics Inc
Buy
$30.7M
-89.2%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Gain Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 59.9% return, outperforming this stock by 132.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 287.4%

Institutional Holdings

  • Greenlight Capital, Inc

    2.23%
  • Raymond James & Associates

    0.99%
  • Royal Bank of Canada

    0.94%
  • Geode Capital Management, LLC

    0.67%
  • Vanguard Group Inc

    0.45%
  • CM Management, LLC

    0.34%

Company Information

gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.

Organization
Gain Therapeutics Inc
Employees
29
CEO
Dr. Khalid Islam Ph.D.
Industry
Miscellaneous

FAQs